QT prolongation occurs when the heart muscle takes longer to contract and relax than usual. It can affect heart rhythms and lead to sudden cardiac arrest. The heart is a muscle that contracts and ...

Boston, MA - Patients who receive high doses of the antidepressants citalopram or escitalopram could potentially develop QT-interval prolongation, a marker of a slight increased risk for ventricular ...

For many years, moderate alcohol intake and its effect on health have been subject to much debate, particularly concerning cardiovascular health. Indeed, light-to-moderate use of alcohol has been ...

February 3, 2006-- A recent analysis of the prospective, population-based Rotterdam Study found that prolongation of the heart-rate corrected QT (QTc) interval increased the risk of sudden cardiac ...

Multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are known to cause cardiac toxicity, but the relative risk (RR) of QTc interval prolongation and ...

A prolonged QT interval creates an electro-physiological environment that is favorable for the development of cardiac arrhythmias. A new study in Holland suggests that yet another group of ...

QT Prolongation Risk Assessed for Non-SSRI Antidepressants Although the FDA requires drug companies to do extensive side-effect testing on their products prior to approval, including QT and QTc ...

Studies comparing MMT to buprenorphine maintenance treatment (BMT) over 5-years found buprenorphine to be a safer drug for opioid maintenance treatment as it had no significant effect on QT ...

A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A. Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and ...

CredibleMeds, a valuable resource for prescribing physicians, now includes information from FDA drug labels to inform prescribers of any ECG monitoring recommendations, warnings for use in congenital ...

Evaluation of utility of pharmacokinetic studies in phase I combination trials. ApoStream, a novel device for antibody-independent capture of circulating cancercells (CCCs) from blood of patients with ...